CB

Corriente Biotechnology Partners

Description

Corriente Biotechnology Partners was added in 2010.

Investor Profile

Corriente Biotechnology Partners has made 1 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series Unknown (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Health Care
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Corriente Biotechnology Partners frequently co-invest with?

BM
Europe, Southern Finland, Finland, Helsinki
Co-Investments: 1
Goldman Sachs
North America, New York, United States, New York
Co-Investments: 1
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
Daiwa SMBC Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
MB
North America, New York, United States, New York
Co-Investments: 1
Rosewood Corporation
North America, Texas, United States, Dallas
Co-Investments: 1
AC
North America, Illinois, United States, Chicago
Co-Investments: 1
Astellas Pharma
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
DC
North America, New York, United States, New York
Co-Investments: 1
Brookside Capital
North America, California, United States, San Francisco
Co-Investments: 1

What are some of recent deals done by Corriente Biotechnology Partners?

FibroGen

San Francisco, California, United States

FibroGen uses its expertise in CTGF and HIF biology to discover, develop, and commercialize novel therapeutics.

BiopharmaBiotechnologyHealth CareTherapeutics
Series UnknownFeb 17, 2005
Amount Raised: $100,000,000